Table 1.
Adjusted by-treatment geometric means and relative bioavailability of dabigatran (total and free) after administration of dabigatran etexilate 220 mg, with and without enoxaparin (n = 23)
| Analyte | Parameter | gMean | Ratio test/reference (%) | 90% Confidence interval | Intra-individual gCV (%) | ||
|---|---|---|---|---|---|---|---|
| Testa (n = 23) | Referenceb (n = 23) | Lower limit | Upper limit | ||||
| Total dabigatran | AUC0-∞ (ng·h/mL) | 774.2 | 921.7 | 84 | 67.2 | 105.0 | 46.1 |
| Cmax (ng/mL) | 99.0 | 115.3 | 86 | 67.0 | 110.0 | 51.9 | |
| Free dabigatran | AUC0-∞ (ng·h/mL) | 591.7 | 700.1 | 85 | 67.5 | 105.9 | 46.6 |
| Cmax (ng/mL) | 78.4 | 90.7 | 86 | 67.5 | 110.8 | 51.9 | |
gMean, Geometric mean; AUC0–∞, area under the concentration–time curve; Cmax, maximum plasma concentration; gCV, geometric coefficient of variation
aTest: dabigatran etexilate after 3-day subcutaneous treatment with enoxaparin
bReference: dabigatran etexilate alone